Real world outcomes with elotuzumab-based therapies for patients with relapsed refractory multiple myeloma: a Mayo Clinic experience

Saved in:
Bibliographic Details
Main Authors: Ricardo D. Parrondo, Saurav Das, Hanna Sledge, Leif Bergsagel, Rafael Fonseca, Nelson Leung, Prashant Kapoor, Morie Gertz, Francis Buadi, Angela Dispenzieri, Jamie Elliott, Andre Fernandez, Caitlin Flott, Asher A. Chanan-Khan, Vivek Roy, Sikander Ailawadhi
Format: Article
Language:English
Published: Nature Publishing Group 2025-05-01
Series:Blood Cancer Journal
Online Access:https://doi.org/10.1038/s41408-025-01310-z
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850270928079945728
author Ricardo D. Parrondo
Saurav Das
Hanna Sledge
Leif Bergsagel
Rafael Fonseca
Nelson Leung
Prashant Kapoor
Morie Gertz
Francis Buadi
Angela Dispenzieri
Jamie Elliott
Andre Fernandez
Caitlin Flott
Asher A. Chanan-Khan
Vivek Roy
Sikander Ailawadhi
author_facet Ricardo D. Parrondo
Saurav Das
Hanna Sledge
Leif Bergsagel
Rafael Fonseca
Nelson Leung
Prashant Kapoor
Morie Gertz
Francis Buadi
Angela Dispenzieri
Jamie Elliott
Andre Fernandez
Caitlin Flott
Asher A. Chanan-Khan
Vivek Roy
Sikander Ailawadhi
author_sort Ricardo D. Parrondo
collection DOAJ
format Article
id doaj-art-971b24003fd2464eae7f4bb29789fd30
institution OA Journals
issn 2044-5385
language English
publishDate 2025-05-01
publisher Nature Publishing Group
record_format Article
series Blood Cancer Journal
spelling doaj-art-971b24003fd2464eae7f4bb29789fd302025-08-20T01:52:24ZengNature Publishing GroupBlood Cancer Journal2044-53852025-05-011511510.1038/s41408-025-01310-zReal world outcomes with elotuzumab-based therapies for patients with relapsed refractory multiple myeloma: a Mayo Clinic experienceRicardo D. Parrondo0Saurav Das1Hanna Sledge2Leif Bergsagel3Rafael Fonseca4Nelson Leung5Prashant Kapoor6Morie Gertz7Francis Buadi8Angela Dispenzieri9Jamie Elliott10Andre Fernandez11Caitlin Flott12Asher A. Chanan-Khan13Vivek Roy14Sikander Ailawadhi15Division of Hematology-Oncology, Mayo Clinic FloridaDivision of Hematology-Oncology, Mayo Clinic FloridaDivision of Hematology-Oncology, Mayo Clinic FloridaDivision of Hematology-Oncology, Mayo ClinicDivision of Hematology-Oncology, Mayo ClinicDivision of Hematology, Mayo ClinicDivision of Hematology, Mayo ClinicDivision of Hematology, Mayo ClinicDivision of Hematology, Mayo ClinicDivision of Hematology, Mayo ClinicDivision of Hematology-Oncology, Mayo Clinic FloridaDivision of Hematology-Oncology, Mayo Clinic FloridaDivision of Hematology-Oncology, Mayo Clinic FloridaDivision of Hematology-Oncology, Mayo Clinic FloridaDivision of Hematology-Oncology, Mayo Clinic FloridaDivision of Hematology-Oncology, Mayo Clinic Floridahttps://doi.org/10.1038/s41408-025-01310-z
spellingShingle Ricardo D. Parrondo
Saurav Das
Hanna Sledge
Leif Bergsagel
Rafael Fonseca
Nelson Leung
Prashant Kapoor
Morie Gertz
Francis Buadi
Angela Dispenzieri
Jamie Elliott
Andre Fernandez
Caitlin Flott
Asher A. Chanan-Khan
Vivek Roy
Sikander Ailawadhi
Real world outcomes with elotuzumab-based therapies for patients with relapsed refractory multiple myeloma: a Mayo Clinic experience
Blood Cancer Journal
title Real world outcomes with elotuzumab-based therapies for patients with relapsed refractory multiple myeloma: a Mayo Clinic experience
title_full Real world outcomes with elotuzumab-based therapies for patients with relapsed refractory multiple myeloma: a Mayo Clinic experience
title_fullStr Real world outcomes with elotuzumab-based therapies for patients with relapsed refractory multiple myeloma: a Mayo Clinic experience
title_full_unstemmed Real world outcomes with elotuzumab-based therapies for patients with relapsed refractory multiple myeloma: a Mayo Clinic experience
title_short Real world outcomes with elotuzumab-based therapies for patients with relapsed refractory multiple myeloma: a Mayo Clinic experience
title_sort real world outcomes with elotuzumab based therapies for patients with relapsed refractory multiple myeloma a mayo clinic experience
url https://doi.org/10.1038/s41408-025-01310-z
work_keys_str_mv AT ricardodparrondo realworldoutcomeswithelotuzumabbasedtherapiesforpatientswithrelapsedrefractorymultiplemyelomaamayoclinicexperience
AT sauravdas realworldoutcomeswithelotuzumabbasedtherapiesforpatientswithrelapsedrefractorymultiplemyelomaamayoclinicexperience
AT hannasledge realworldoutcomeswithelotuzumabbasedtherapiesforpatientswithrelapsedrefractorymultiplemyelomaamayoclinicexperience
AT leifbergsagel realworldoutcomeswithelotuzumabbasedtherapiesforpatientswithrelapsedrefractorymultiplemyelomaamayoclinicexperience
AT rafaelfonseca realworldoutcomeswithelotuzumabbasedtherapiesforpatientswithrelapsedrefractorymultiplemyelomaamayoclinicexperience
AT nelsonleung realworldoutcomeswithelotuzumabbasedtherapiesforpatientswithrelapsedrefractorymultiplemyelomaamayoclinicexperience
AT prashantkapoor realworldoutcomeswithelotuzumabbasedtherapiesforpatientswithrelapsedrefractorymultiplemyelomaamayoclinicexperience
AT moriegertz realworldoutcomeswithelotuzumabbasedtherapiesforpatientswithrelapsedrefractorymultiplemyelomaamayoclinicexperience
AT francisbuadi realworldoutcomeswithelotuzumabbasedtherapiesforpatientswithrelapsedrefractorymultiplemyelomaamayoclinicexperience
AT angeladispenzieri realworldoutcomeswithelotuzumabbasedtherapiesforpatientswithrelapsedrefractorymultiplemyelomaamayoclinicexperience
AT jamieelliott realworldoutcomeswithelotuzumabbasedtherapiesforpatientswithrelapsedrefractorymultiplemyelomaamayoclinicexperience
AT andrefernandez realworldoutcomeswithelotuzumabbasedtherapiesforpatientswithrelapsedrefractorymultiplemyelomaamayoclinicexperience
AT caitlinflott realworldoutcomeswithelotuzumabbasedtherapiesforpatientswithrelapsedrefractorymultiplemyelomaamayoclinicexperience
AT asherachanankhan realworldoutcomeswithelotuzumabbasedtherapiesforpatientswithrelapsedrefractorymultiplemyelomaamayoclinicexperience
AT vivekroy realworldoutcomeswithelotuzumabbasedtherapiesforpatientswithrelapsedrefractorymultiplemyelomaamayoclinicexperience
AT sikanderailawadhi realworldoutcomeswithelotuzumabbasedtherapiesforpatientswithrelapsedrefractorymultiplemyelomaamayoclinicexperience